Sanofi gets EU approval for Sarclisa for newly diagnosed patients
Sanofi (NASDAQ:SNY) has received EU regulatory approval for its drug Sarclisa for the treatment of newly diagnosed multiple myeloma patients. The drug was approved for use in combination with a ...
STAT4h
Pharmalittle: We’re reading about a cancer therapy’s gold rush, FDA warning Sanofi, and more news
A Belgian court dismissed a lawsuit against EU chief Ursula von der Leyen centered on text messages she exchanged with Pfizer ...
clinicaltrialsarena8h
FDA lifts hold on Opella’s trial to support switch of Cialis to OTC drug
The US FDA has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer healthcare business, Opella.
HB Wealth Management LLC Raises Stock Position in Sanofi (NASDAQ:SNY)
HB Wealth Management LLC increased its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 151.8% in the fourth ...
Sanofi Announces Expanded Marketing Authorization For Sarclisa In The EU - Quick Facts
Sanofi (SNYNF, SNY) said the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and ...
STAT23h
Sanofi is warned by the FDA over ‘significant’ problems at a key manufacturing plant
The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...